Windlas Biotech has informed that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 12, 2024, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. In accordance with the code of conduct to regulate, monitor and report trading by Designated Persons of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015, the Trading Window of the Company is already closed from October 01, 2024, vide its letter dated September 30, 2024, and it shall reopen on November 15, 2024.
The above information is a part of company’s filings submitted to BSE.